Rhoen Klinikum (ETR:RHK) Given a €19.75 Price Target by Berenberg Bank Analysts

Berenberg Bank set a €19.75 ($22.97) target price on Rhoen Klinikum (ETR:RHK) in a report released on Friday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.

RHK has been the topic of a number of other research reports. Independent Research set a €19.80 ($23.02) price objective on shares of Rhoen Klinikum and gave the stock a neutral rating in a research report on Thursday, November 21st. Credit Suisse Group set a €16.50 ($19.19) price objective on shares of Rhoen Klinikum and gave the stock a sell rating in a research report on Tuesday, November 19th. Two equities research analysts have rated the stock with a sell rating and three have given a hold rating to the company. The stock has an average rating of Hold and an average price target of €19.17 ($22.29).

Shares of Rhoen Klinikum stock opened at €16.36 ($19.02) on Friday. The firm’s 50 day moving average price is €16.69 and its 200-day moving average price is €19.24. The company has a quick ratio of 1.96, a current ratio of 2.11 and a debt-to-equity ratio of 14.68. Rhoen Klinikum has a 52-week low of €15.72 ($18.28) and a 52-week high of €27.40 ($31.86). The company has a market cap of $1.10 billion and a P/E ratio of 27.27.

Rhoen Klinikum Company Profile

RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services primarily in the areas of cardiovascular, neurology, oncology, pulmonology, orthopedic, accident surgery; rehabilitation and nursing services to the elderly; and thoracic, tumors, and psychosomatic, as well as spinal, column, and joints diseases.

Further Reading: What is a stock split?

Analyst Recommendations for Rhoen Klinikum (ETR:RHK)

Receive News & Ratings for Rhoen Klinikum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhoen Klinikum and related companies with MarketBeat.com's FREE daily email newsletter.